- Home
- APVO vs SBFM Comparison
APVO vs SBFM Comparison
Compare APVO & SBFM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- SBFM
- Stock Information
- Founded
- APVO 2016
- SBFM 2006
- Country
- APVO United States
- SBFM United States
- Employees
- APVO N/A
- SBFM N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- SBFM Biotechnology: Pharmaceutical Preparations
- Sector
- APVO Health Care
- SBFM Health Care
- Exchange
- APVO Nasdaq
- SBFM Nasdaq
- Market Cap
- APVO 4.1M
- SBFM 4.6M
- IPO Year
- APVO N/A
- SBFM N/A
- Fundamental
- Price
- APVO $4.95
- SBFM $1.51
- Analyst Decision
- APVO Strong Buy
- SBFM Strong Buy
- Analyst Count
- APVO 1
- SBFM 1
- Target Price
- APVO $5,920.00
- SBFM $15.00
- AVG Volume (30 Days)
- APVO 393.8K
- SBFM 104.9K
- Earning Date
- APVO 05-14-2025
- SBFM 05-15-2025
- Dividend Yield
- APVO N/A
- SBFM N/A
- EPS Growth
- APVO N/A
- SBFM N/A
- EPS
- APVO N/A
- SBFM N/A
- Revenue
- APVO N/A
- SBFM $36,234,578.00
- Revenue This Year
- APVO N/A
- SBFM $192.48
- Revenue Next Year
- APVO N/A
- SBFM N/A
- P/E Ratio
- APVO N/A
- SBFM N/A
- Revenue Growth
- APVO N/A
- SBFM 35.51
- 52 Week Low
- APVO $4.30
- SBFM $1.17
- 52 Week High
- APVO $658.60
- SBFM $11.39
- Technical
- Relative Strength Index (RSI)
- APVO 28.32
- SBFM 54.20
- Support Level
- APVO $4.30
- SBFM $1.37
- Resistance Level
- APVO $5.18
- SBFM $1.56
- Average True Range (ATR)
- APVO 1.22
- SBFM 0.08
- MACD
- APVO 0.72
- SBFM 0.02
- Stochastic Oscillator
- APVO 6.47
- SBFM 73.68
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.